FIELD: biotechnology.
SUBSTANCE: invention relates to an immunoreactive cell including an antigen-recognizing receptor that binds an antigen, and binding of the antigen-recognizing receptor to an antigen activates the immunoreactive cell, and a soluble single-chain variable fragment (scFv), as well as to a composition containing it. Also the following is disclosed: a method for producing an immunoreactive cell that includes introducing into the immunoreactive cell a nucleic acid sequence that encodes a single-chain variable fragment (scFv), where the immunoreactive cell contains an antigen-recognizing receptor that binds the antigen.
EFFECT: invention is effective for reducing tumor mass and increasing the survival of an individual with neoplasia.
37 cl, 29 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2729118C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT RECEPTOR BOUND TO G-PROTEINS, AND THEIR APPLICATION | 2015 |
|
RU2762359C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
